A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...
An experimental therapeutic human papillomavirus (HPV) vaccine showed promise in inducing regression of precancerous cervical lesions as well as viral clearance in patients with cervical ...
50% of patients with CIN3 had histopathological complete response; 63% had HPV16 clearance. (HealthDay News) — For patients with human papillomavirus (HPV) type 16 (HPV16)-positive cervical ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a Phase II clinical trial published ...
Short-interval HPV retesting showed promise for identifying high-risk cervical neoplasia in HPV-positive patients. A positive repeat HPV test at 2 months had 82-88% sensitivity for high-grade cervical ...
Both complete and incomplete vaccination in individuals were associated with a significantly lower detection rate of high-risk HPV 16/18 and 16/18/31/33/45 in CIN2 compared with no vaccination.
PHILADELPHIA – A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results